![](https://etimg.etb2bimg.com/thumb/msid-112065465,imgsize-56112,width-1200,height=765,overlay-ethealth/pharma/drug-approvals-launches/eu-regulator-backs-use-of-gsks-rsv-shot-in-adults-aged-50-to-59.jpg)
Search News
-
Published on Jul 27, 2024Source: ET Healthworld - Center-right
-
Published on Jul 26, 2024
Ontario offering RSV vaccines to more young children and to pregnant women
Ontario is expanding its respiratory virus vaccination program this year for infants, high-risk children and pregnant women ahead of the fall flu season. The government announced Thursday that it would be significantly expanding eligibility for respiratory …
Source: Global News - Neutral -
Published on Jul 26, 2024
RSV Vaccination: Building Trust in Communities
Pharmacists are the cornerstone of health care, connecting prescribing physicians and their local communities. In particular, patients in underserved communities do not have easy access to health care or regular physician visits, so as the most accessible …
Source: Pharmacy Times - Neutral -
Published on Jul 26, 2024
Universal Immunization Program for Infants During Ontario's RSV Season
(Precision Vaccinations News)The Ontario Ministry of Health has announced the first publicly funded universal program with Beyfortus® (nirsevimab) for all newborns and infants born in 2024 and through the 2024-2025 respiratory syncytial virus (RSV) season …
Source: Precision Vaccinations - Label Pending -
Published on Jul 26, 2024
Ontario expanding access to RSV vaccines for young children, pregnant women
TORONTO — Ontario is doubling the number of children eligible for vaccination against a virus that can make young kids very sick. The province says infants and high-risk children up to two years old will have access to new immunization to protect against …
Source: Midland Today - Label Pending -
Published on Jul 26, 2024
Investigational RSV Monoclonal Antibody Meets all Trial Endpoints
This week, Merck announced positive topline results from its phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial …
Source: ContagionLive - Neutral -
Published on Jul 26, 2024
EU regulator backs use of GSK's RSV shot in adults aged 50 to 59
(Reuters) -The European Union health regulator on Friday recommended expanded use of GSK’s respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59. Any recommendation by the European Medicines Agency’s Committee for Medicinal Products …
Source: WTVB - Label Pending -
Published on Jul 26, 2024
Quebec's Committee on Immunization recommends use of RSV vaccines, including Arexvy, for older adult populations at risk ...
The Committee on Immunization of Quebec (Comité sur l’immunisation du Québec - CIQ) has recommended use of RSV (respiratory syncytial virus) vaccines, including Arexvy, for the prevention of RSV among older adults at increased risk of severe outcomes from …
Source: Pharmabiz.com - Neutral -
Published on Jul 25, 2024
IL Health System Launches RPM Program For Children With RSV
With the goal of reducing the number of occupied hospital beds, OSF HealthCare has added a remote patient monitoring (RPM) program to OSF OnCall Digital Health that will provide at-home care for infants and toddlers with respiratory syncytial virus …
Source: mHealthIntelligence - Neutral -
Published on Jul 25, 2024
RSV Monoclonal Antibody Sales Surpass $19 Million
(Precision Vaccinations News)Sanofi today announced strong performance and increasing sales growth. In Q2 2024, Sanofi's sales were €10,745 million, up 10.2%. In a press release on July 25, 2024, Paul Hudson, CEO, commented, “We are continuing our …
Source: Precision Vaccinations - Label Pending